18 to 75 years old | Indago Research

A clinical research study for people living with type 2 diabetes and excess weight GN02 Study

The GN02 study is a new clinical research study from Eli Lilly and Company. GN02 is a weight management study. It will test if an investigational medicine can safely reduce body weight in people with type 2 diabetes and obesity or overweight when compared to placebo.

Investigational medicine means it is still being tested in clinical research studies. A placebo looks the same as an investigational medicine but does not have any real medicine in it.

Can I join this study?

Yes, you may be able to join the study if you:

are aged 18 to 75 years
cannot become pregnant
have type 2 diabetes that you treated with diet and exercise alone or with a stable dose of metformin.
have not taken insulin in the past year, and
have a BMI of 27kg/m ² or more

BMI stands for body mass index. It is a number that compares a person’s weight to their height. It can be used to tell if a person may be at risk of some health conditions.

For more information: 786-772-0510

18 to 75 years old

A clinical research study for people with obesity or overweight GN01

The GN01 study is a new clinical research study from Eli Lilly and Company. It will test if an investigational medicine (a medicine being studied) is safe and could reduce weight in people with obesity or overweight.

18 to 75 years old Overweight

Are you interested in participating in this clinical trial?

Controlled Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants with Obesity or Overweight

18 to 75 years old Diabetes Obesity Overweight

A clinical research study for people with obesity or overweight and type 2 diabetes

LAA2 is a new clinical research study from Eli Lilly and Company. It is testing if an investigational medicine (a medicine being studied) may help treat people with obesity or overweight and type 2 diabetes.

18 to 75 years old Bad Cholesterol

Are you an Adult living with high levels of bad cholesterol?

This clinical trial’s purpose is to test a new study drug, called AZD0780. The study drug is a small molecule PCSK9 inhibitor that aims to lower the levels of “bad cholesterol” in the blood.

Volunteers who join the trial will take AZD0780(study drug) orally, every day for 12 weeks, which is about three months. Your participation in the study will help to determine the
effectiveness, safety, and tolerability of AZD0780(study drug) and how it affects LDL-C (bad cholesterol) levels and levels of other types of fat in your blood.

You may qualify if you:

Are male or female of non-childbearing potential within an age range from 18 to 75 years.
Fasting LDL-C levels (bad cholesterol): Between 70mg/dL (1.8 mmol/L) and < 190 mg/dL (4.9 mmol/L).
Fasting triglycerides: < 400 mg/dL (< 4.52 mmol/L).
Are receiving moderate or high-intensity statin therapy as per ACC/AHA (at least 2 months prior to screening).
Body mass index (BMI): ≥ 19.0 kg/m2.
Are capable of providing signed informed consent and comply with study requirements.

Contact us for more information: 786-772-0510